PerkinElmer, Inc. completed the acquisition of SYM-BIO Lifescience, a Shanghai company that produces diagnostic instruments and their reagents. The price was $63.7 million (435 million RMB), paid in cash. The acquisition is a very good fit with PerkinElmer’s existing business. SYM-BIO Lifescience is a major supplier of diagnostics to China hospitals, with an emphasis on infectious diseases. This is complimentary to PerkinElmer’s portfolio of diagnostic devices, which specializes in prenatal and newborn screening. More details...

Stock Symbol: (NYSE: PKI)